A pioneering Newcastle University spin-out specialising in early-stage skin cancer testing is set to accelerate its potentially life-saving work with a £2.45m investment.
AMLo Biosciences Ltd (AMLo) was first launched at the university five years ago and has developed its first product AMBLo, a melanoma test set to go to market in the UK, US and Australia.
The innovative medical device has the potential to save thousands of lives every year as well as reassure thousands of others that their early stage skin cancer will not progress.
